These structures present the new scaffold of 1,2,3-triazolium salts for drug development as the current therapy in Alzheimer’s disease (AD) are selective AChE inhibitors, while in Parkinson’s and all stages of AD, non-selective inhibitors of ChE are preferred. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.